EUVIMEDEUVIMED entdecken
Crossref

Response to Comment on Young et al. Precision Prescribing of SGLT2 Inhibitors in Individuals With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation Study

Katherine G. Young, Andrew P. McGovern, Rhian Hopkins, Thijs T. Jansz, Beverley M. Shields, John M. Dennis

Diabetes Care · 01.12.2026 · 49 (12) · e222-e223

DOI: 10.2337/dci26-0132 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Care, online erschienen am 20.11.2026. Verfasst von Katherine G. Young und 5 weiteren Autor:innen. Die Arbeit nennt 3 Literaturangaben. Gefördert von: Medical Research Council.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Förderung

  • Medical Research Council

Zitieren

APA

Young, K. G., McGovern, A. P., Hopkins, R., Jansz, T. T., Shields, B. M., & Dennis, J. M. (2026). Response to Comment on Young et al. Precision Prescribing of SGLT2 Inhibitors in Individuals With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation Study. Diabetes Care, 49(12), e222-e223. https://doi.org/10.2337/dci26-0132

Vancouver

Young KG, McGovern AP, Hopkins R, Jansz TT, Shields BM, Dennis JM. Response to Comment on Young et al. Precision Prescribing of SGLT2 Inhibitors in Individuals With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation Study. Diabetes Care. 2026;49(12):e222-e223. doi:10.2337/dci26-0132

BibTeX
@article{Young2026,
  author = {Young, Katherine G. and McGovern, Andrew P. and Hopkins, Rhian and Jansz, Thijs T. and Shields, Beverley M. and Dennis, John M.},
  title = {Response to Comment on Young et al. Precision Prescribing of SGLT2 Inhibitors in Individuals With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation Study},
  journal = {Diabetes Care},
  year = {2026},
  volume = {49},
  number = {12},
  pages = {e222--e223},
  doi = {10.2337/dci26-0132}
}
Kostenlos starten →